RenovoRx to Present New Clinical Data at 2026 SIO Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy RNXT?
RenovoRx announced that new clinical data will be presented at the 2026 Society of Interventional Oncology, SIO, Annual Scientific Meeting on February 6, 2026. The clinical data abstract entitled, "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors," was led by Christopher Laing, MD of Sutter Health in California. The study explores a simplified method for measuring intra-arterial pressure during procedures that use the TAMP therapy platform enabled by the RenovoCath catheter. The findings in this study demonstrate that a simplified, external pressure transducer provides reliable and reproducible intra-arterial pressure measurements during TAMP procedures, with strong correlation to intravascular pressure wire measurements in a porcine model.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RNXT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RNXT
Wall Street analysts forecast RNXT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RNXT is 5.63 USD with a low forecast of 3.00 USD and a high forecast of 12.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 0.951
Low
3.00
Averages
5.63
High
12.50
Current: 0.951
Low
3.00
Averages
5.63
High
12.50
About RNXT
RenovoRx, Inc. is a clinical and a commercial biopharmaceutical company. Its lead product RenovoCath a local drug delivery device, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents. In addition to the RenovoCath device, RenovoRx is also evaluating the novel Phase III drug-device combination oncology product candidate (intra-arterial gemcitabine, known as IAG). The combination of intra-arterial infusion of chemotherapy, gemcitabine, and the RenovoCath device is being evaluated for the treatment of locally advanced pancreatic cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RenovoRx Announces New Clinical Data Presentation
- Clinical Data Presentation: RenovoRx will present new clinical data at the Society of Interventional Oncology Annual Meeting on February 6, 2026, focusing on real-time intravascular pressure measurements aimed at optimizing drug delivery in tumors, potentially enhancing treatment outcomes.
- Innovative Research Method: Led by Dr. Christopher Laing from Sutter Health, the study explores real-time intra-arterial pressure measurement methods using the adjustable double-balloon catheter within the TAMP therapy platform, demonstrating potential for optimizing targeted chemotherapy delivery.
- Reliability Validation: Findings indicate that an external pressure transducer provides reliable intra-arterial pressure measurements during TAMP procedures, showing strong correlation with intravascular pressure wire measurements in a porcine model, highlighting opportunities for procedural optimization.
- Clinical Application Prospects: Dr. Ramtin Agah, RenovoRx's Chief Medical Officer, emphasized that routine intra-arterial monitoring could enhance standardization and optimize delivery conditions, potentially improving clinical outcomes and advancing the commercialization of the TAMP therapy platform.
See More
Oncolytics Biotech's Breakthroughs in Cancer Treatment
- Market Potential: The global oncology market is projected to reach $668 billion by 2034, positioning companies like Oncolytics Biotech at the forefront of this rapid growth, particularly in innovative treatments for gastrointestinal cancers, indicating strong market demand and investment appeal.
- Clinical Trial Progress: Oncolytics Biotech's pelareorep achieved a 33% response rate in colorectal cancer patients, significantly surpassing the 6-11% typical response rates of conventional chemotherapy, which not only enhances treatment efficacy but also has the potential to redefine treatment standards in this field, bolstering the company's competitive edge.
- Management Team Upgrade: The recent appointments of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both with extensive clinical trial experience, will provide critical support for Oncolytics' execution of complex multi-country registration trials, ensuring rapid and compliant advancement.
- FDA Trial Design Approval: Oncolytics has secured FDA approval for its Phase 3 trial design for pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial planned for this notoriously difficult-to-treat disease, further solidifying its leadership position in oncology innovation.
See More
Oncolytics Biotech's Breakthroughs in Cancer Treatment
- Market Potential: The global oncology market is projected to reach $668 billion by 2034, positioning Oncolytics Biotech at the forefront of this rapid growth, particularly in the treatment of gastrointestinal cancers through innovative immunotherapy.
- Clinical Trial Progress: Oncolytics Biotech's pelareorep achieved a 33% response rate in colorectal cancer patients, significantly surpassing the 6-11% response rates typical of standard chemotherapy, indicating a potential shift in treatment paradigms.
- Management Team Upgrade: The company appointed two key executives, John McAdory and Yujun Wu, with extensive experience in complex late-stage clinical trials and biostatistics, respectively, which will provide robust support for Oncolytics' clinical trial execution.
- FDA Trial Design Approval: Oncolytics has secured FDA approval for its Phase 3 trial design for pancreatic cancer, making it the only immunotherapy registration trial currently planned for this notoriously difficult-to-treat disease, marking a significant advancement for the company.
See More
RenovoRx to Present New Research at 2026 SIO Meeting
- Research Presentation: RenovoRx's abstract will be showcased at the 2026 SIO Annual Meeting, focusing on optimizing chemotherapy delivery through a double-balloon catheter, highlighting the company's innovative potential in oncology treatment.
- Clinical Data Sharing: Led by Dr. Christopher Laing from Sutter Health, the study is set for presentation on February 6, 2026, emphasizing the significance of real-time intra-arterial pressure monitoring in drug delivery, potentially paving the way for personalized treatment approaches.
- Market Outlook: As an FDA-cleared drug delivery device, RenovoCath is expected to drive the company's commercialization efforts in the oncology market, having generated approximately $900,000 in sales revenue in the first nine months of 2025, indicating growing market demand.
- Strategic Development: RenovoRx is actively exploring further collaborations with medical device commercial partners to meet the increasing demand for RenovoCath, reflecting the company's focus on future market opportunities and strategic positioning.
See More
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
See More
Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044
- IP Expansion: Oncolytics Biotech filed a Track 1 prioritized examination patent application with the USPTO in Q3 2025 for manufacturing innovations related to pelareorep, which, if granted, could extend its commercial protection to 2044, thereby enhancing its competitive market position.
- Significant Clinical Results: Pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 6-11% response rate for chemotherapy alone, potentially driving a $20 billion market growth.
- Expert Team Expansion: Oncolytics Biotech expanded its Gastrointestinal Tumor Scientific Advisory Board by adding three globally recognized experts from leading cancer centers, enhancing academic support for its clinical research and further elevating the company's reputation in the industry.
- Successful FDA Alignment: The company secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial planned for this disease in the market.
See More
RenovoRx Announces New Clinical Data Presentation
- Clinical Data Presentation: RenovoRx will present new clinical data at the Society of Interventional Oncology Annual Meeting on February 6, 2026, focusing on real-time intravascular pressure measurements aimed at optimizing drug delivery in tumors, potentially enhancing treatment outcomes.
- Innovative Research Method: Led by Dr. Christopher Laing from Sutter Health, the study explores real-time intra-arterial pressure measurement methods using the adjustable double-balloon catheter within the TAMP therapy platform, demonstrating potential for optimizing targeted chemotherapy delivery.
- Reliability Validation: Findings indicate that an external pressure transducer provides reliable intra-arterial pressure measurements during TAMP procedures, showing strong correlation with intravascular pressure wire measurements in a porcine model, highlighting opportunities for procedural optimization.
- Clinical Application Prospects: Dr. Ramtin Agah, RenovoRx's Chief Medical Officer, emphasized that routine intra-arterial monitoring could enhance standardization and optimize delivery conditions, potentially improving clinical outcomes and advancing the commercialization of the TAMP therapy platform.
See More
Oncolytics Biotech's Breakthroughs in Cancer Treatment
- Market Potential: The global oncology market is projected to reach $668 billion by 2034, positioning companies like Oncolytics Biotech at the forefront of this rapid growth, particularly in innovative treatments for gastrointestinal cancers, indicating strong market demand and investment appeal.
- Clinical Trial Progress: Oncolytics Biotech's pelareorep achieved a 33% response rate in colorectal cancer patients, significantly surpassing the 6-11% typical response rates of conventional chemotherapy, which not only enhances treatment efficacy but also has the potential to redefine treatment standards in this field, bolstering the company's competitive edge.
- Management Team Upgrade: The recent appointments of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vice President, Head of Biostatistics, both with extensive clinical trial experience, will provide critical support for Oncolytics' execution of complex multi-country registration trials, ensuring rapid and compliant advancement.
- FDA Trial Design Approval: Oncolytics has secured FDA approval for its Phase 3 trial design for pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial planned for this notoriously difficult-to-treat disease, further solidifying its leadership position in oncology innovation.
See More
Oncolytics Biotech's Breakthroughs in Cancer Treatment
- Market Potential: The global oncology market is projected to reach $668 billion by 2034, positioning Oncolytics Biotech at the forefront of this rapid growth, particularly in the treatment of gastrointestinal cancers through innovative immunotherapy.
- Clinical Trial Progress: Oncolytics Biotech's pelareorep achieved a 33% response rate in colorectal cancer patients, significantly surpassing the 6-11% response rates typical of standard chemotherapy, indicating a potential shift in treatment paradigms.
- Management Team Upgrade: The company appointed two key executives, John McAdory and Yujun Wu, with extensive experience in complex late-stage clinical trials and biostatistics, respectively, which will provide robust support for Oncolytics' clinical trial execution.
- FDA Trial Design Approval: Oncolytics has secured FDA approval for its Phase 3 trial design for pancreatic cancer, making it the only immunotherapy registration trial currently planned for this notoriously difficult-to-treat disease, marking a significant advancement for the company.
See More
RenovoRx to Present New Research at 2026 SIO Meeting
- Research Presentation: RenovoRx's abstract will be showcased at the 2026 SIO Annual Meeting, focusing on optimizing chemotherapy delivery through a double-balloon catheter, highlighting the company's innovative potential in oncology treatment.
- Clinical Data Sharing: Led by Dr. Christopher Laing from Sutter Health, the study is set for presentation on February 6, 2026, emphasizing the significance of real-time intra-arterial pressure monitoring in drug delivery, potentially paving the way for personalized treatment approaches.
- Market Outlook: As an FDA-cleared drug delivery device, RenovoCath is expected to drive the company's commercialization efforts in the oncology market, having generated approximately $900,000 in sales revenue in the first nine months of 2025, indicating growing market demand.
- Strategic Development: RenovoRx is actively exploring further collaborations with medical device commercial partners to meet the increasing demand for RenovoCath, reflecting the company's focus on future market opportunities and strategic positioning.
See More
Bark Inc (BARK) Shares Surge 19.9% on Acquisition Proposal from Great Dane
- Acquisition Proposal: Great Dane's submission of a non-binding acquisition letter to Bark Inc has led to a 19.9% surge in Bark's pre-market share price to $0.74, indicating strong market enthusiasm for the potential acquisition.
- Market Reaction: The significant rise in Bark Inc's stock price reflects investor optimism regarding the company's future, which may also attract more investor attention and enhance market liquidity for the stock.
- Industry Dynamics: In pre-market trading, Signing Day Sports Inc saw a 43.7% increase, while Ping An Biomedical Co Ltd rose 34.3%, highlighting strong market interest in the biotech and sports sectors, which could influence Bark Inc's market positioning.
- Investor Confidence: The rebound in Bark Inc's stock price may bolster investor confidence in the company, especially after recent market volatility, as the acquisition proposal provides new momentum for future growth.
See More
Oncolytics Biotech Fortifies IP Protection, Extends Pelareorep Commercial Runway to 2044
- IP Expansion: Oncolytics Biotech filed a Track 1 prioritized examination patent application with the USPTO in Q3 2025 for manufacturing innovations related to pelareorep, which, if granted, could extend its commercial protection to 2044, thereby enhancing its competitive market position.
- Significant Clinical Results: Pelareorep achieved a 33% objective response rate in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer patients, significantly higher than the 6-11% response rate for chemotherapy alone, potentially driving a $20 billion market growth.
- Expert Team Expansion: Oncolytics Biotech expanded its Gastrointestinal Tumor Scientific Advisory Board by adding three globally recognized experts from leading cancer centers, enhancing academic support for its clinical research and further elevating the company's reputation in the industry.
- Successful FDA Alignment: The company secured FDA alignment on its Phase 3 study design for pelareorep in first-line metastatic pancreatic cancer, marking the imminent launch of the only immunotherapy registration trial planned for this disease in the market.
See More
